Evaluation and comparison of the effectiveness of Hyper CVAD and Arsenic/ interferon/ zidovudine (As/IFN/AZT) treatment regimens in patients with acute Adult T-cell leukemia (ATL).

Start Date25 Mar 2022

Sponsor / Collaborator

Mashhad University of Medical Sciences

ChiCTR1900026933 / SuspendedPhase 1IIT

Bioequivalance of Zidovudine and Lamivudine Tablets(Fasting) in the Human Body: A randomized cross-over controlled trial

Start Date28 Oct 2019

Sponsor / Collaborator-

NCT03988452 / Unknown statusPhase 3IIT

Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa

This trial evaluates options for second-line antiretroviral therapy in patients failing on a non-nucleoside reverse transcriptase inhibitor (NNRTI) and tenofovir (TDF)-based first-line regimen in the setting of the public health approach in sub-Saharan Africa (with assumed substantial nucleoside reverse transcriptase inhibitor (NRTI) cross-resistance). The trial tests two hypotheses. Firstly that a regimen of dolutegravir (DTG) with two NRTIs is non-inferior to a regimen of ritonavir-boosted darunavir (DRV/r) with two NRTIs. Secondly that continuing an NRTI regimen of TDF and lamivudine (3TC) is non-inferior to switching to zidovudine (ZDV) and 3TC.
The trial is a parallel group, open-label, multi-centre, factorial (2X2) randomised, controlled trial. Patients will be randomised to either DTG or DRV/r with a second randomisation to ZDV and 3TC or TDF and 3TC. Treatment efficacy will be monitored by testing viral load (VL). Analyses will compare DRV/r with DTG; and ZDV/3TC with TDF/3TC by intention to treat analysis on the primary outcome parameter of plasma VL below 400 copies/ml at 48 weeks. Trial follow-up will continue to 96 weeks.

Start Date30 Jul 2019

Sponsor / Collaborator

Makerere University

100 Clinical Results associated with Zidovudine

100 Translational Medicine associated with Zidovudine

100 Patents (Medical) associated with Zidovudine

10,712

Literatures (Medical) associated with Zidovudine

01 Feb 2025·CURRENT CANCER DRUG TARGETS

Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression

Article

Author: Suseela, Rangaraj ; Miji, Thandaserry Vasudevan ; Bharathi, Muruganantham ; Muthusami, Sridhar ; Almoallim, Hesham S. ; Kaviyaprabha, Rangaraj ; Thangaleela, Subramanian ; Sivakumar, Priyadarshini

Introduction::

This study delved into the role of Kinase Insert Domain Receptor (KDR) and its associated miRNAs in renal cell carcinoma through an extensive computational analysis. The potential of our findings to guide future research in this area is significant.

Methods::

Our methods, which included the use of UALCAN and GEPIA2 databases, as well as miRDB, MirDIP, miRNet v2.0, miRTargetLink, MiEAA v2.1, TarBase v8.0, INTERNET, and miRTarBass, were instrumental in identifying the regulation of miRNA associated with KDR expression. The predicted miRNA was validated with the TCGA-KIRC patients’ samples by implementing CancerMIRNome. The TargetScanHuman v8.0 was implemented to identify the associations between human miRNAs and KDR. A Patch Dock server analyzed the interactions between hsa-miR-200b-3p-KDR and hsa-miR-200b-3p with KDR.

Results::

The KDR expression rate was investigated in the Kidney Renal Cell Carcinoma (KIRC) samples, and adjacent normal tissues revealed that the expression rate was significantly higher than the normal samples, which was evident from the strong statistical significance (P = 1.63e-12). Likely, the KDR ex-pression rate was estimated as high at tumor grade 1 and gradually decreased till the metastasis grade, reducing the survival rate of the KIRC patients. To identify these signals early, we predicted a miRNA that could trigger the expression of KDR. Furthermore, we uncovered the potential associations between miR-200c-3p expressions by regulating KDR towards the progression of KIRC.

Discussion::

Upon examining the outcome, it became evident that miR-200c-3p was significantly down-regulated in KIRC compared to the normal samples. Moreover, the negative correlation was obtained for hsa-miR-200c-3p (R = - 0.276) along with the KDR expression describing that the increased rate of hsa-miR-200c-3p might reduce the KDR expression rate, which may suppress the KIRC initiation or progres-sion.

Conclusion::

The in-silico analysis indicated that the significant increase in KDR expression during the initiation of KIRC could serve as an early diagnostic marker. Moreover, KDR could be utilized to identify advancements in KIRC stages. Additionally, hsa-miR-200c-3p was identified as a potential regulator capable of downregulating and upregulating KDR expression among the 24 miRNAs screened. This find-ing holds promise for future research endeavors. Concurrent administration of the FDA-approved 5-fluor-ouracil with KIRC drugs, such as sorafenib, zidovudine, and everolimus, may have the potential to en-hance the therapeutic efficacy in downregulating hsa-miR-200c-3p. However, further in vitro studies are imperative to validate these findings and gain a comprehensive understanding of the intricate regulatory interplay involving hsa-miR-200c-3p, KDR, 5-fluorouracil, and other FDA-approved drugs for the treat-ment of KIRC. This will facilitate the identification of KIRC stage progression and its underlying pre-ventative mechanisms.

01 Jan 2025·Biomaterials advances

Continuously producible aztreonam-loaded inhalable lipid nanoparticles for cystic fibrosis-associated Pseudomonas aeruginosa infections – Development and in-vitro characterization

Article

Author: Shaik, Abdul A ; Shaik, Abdul A. ; Goyal, Mimansa ; Shukla, Snehal K ; Kunda, Nitesh K ; Diwan, Rimpy ; Shukla, Snehal K. ; Chauhan, Gautam ; Sawant, Shruti S ; Gupta, Vivek ; Kunda, Nitesh K. ; Mokashi, Meghana ; Sawant, Shruti S.

Cystic fibrosis (CF) is a genetic disorder affecting nearly 105,000 patients worldwide and is characterized by poor respiratory function due to accumulation of thick mucus in the lungs, which not just acts as a physical barrier, but also provides a breeding ground for bacterial infections. These infections can be controlled with the help of antibiotics which can be delivered directly into the lungs for amplifying the local anti-bacterial effect. More than 50 % of CF patients are associated with Pseudomonas aeruginosa infection in their lungs which requires antibiotics such as Aztreonam (AZT). In this study, we prepared inhalable AZT-loaded lipid nanoparticles using Hot-melt extrusion (HME) coupled with probe sonication to target Pseudomonas aeruginosa infection in the lungs. The optimized nanoparticles were tested for physicochemical properties, stability profile, in-vitro aerosolization, and antimicrobial activity against Pseudomonas aeruginosa. The optimized nanoparticles with a PEI concentration of 0.1 % demonstrated a uniform particle size of <50 nm, a spherical shape observed under a transmission electron microscope, and >70 % drug entrapment. Incorporating cationic polymer, PEI, resulted in sustained drug release from the lipid nanoparticles. The in-vitro aerosolization studies exhibited a mass median aerodynamic diameter (MMAD) of <4.3 μm, suggesting deposition of the nanoparticles in the respirable airway. The antimicrobial activity against Pseudomonas aeruginosa showed the minimum inhibitory concentration of the formulation is 2-fold lower than plain AZT. Stability profile showed the formulations are stable after exposure to accelerated conditions. In conclusion, hot-melt extrusion in combination with probe sonication can be used as a potential method for the continuous production of AZT-loaded lipid nanoparticles with enhanced anti-bacterial activity.

01 Jan 2025·BIOORGANIC CHEMISTRY

Discovery of pentacyclic triterpene conjugates as HBV polymerase/NTCP dual-targeting inhibitors with potent anti-HBV activities

Article

Author: Xu, Jianling ; Duan, Ao ; Li, Wenzhang ; Chen, Yixin ; Zhu, Quanhong ; Zhu, Yongyan ; Duan, Meitao ; Tian, Shuo ; Tao, Huaming ; Zhou, Zishan ; Tao, Hongquan ; Yang, Haocheng

The inhibition of HBV DNA and elimination of HBsAg has already been established as an indicator for HBV clinic cure, and a novel dual-targeting inhibitors of HBV polymerase/entry are designed and synthesized in this study. Pentacyclic triterpenes (PTs) scaffold of exhibiting a high affinity to NTCP, including glycyrrhitinic acid (GA), oleanolic acid (OA), ursolic acid (UA), and betulinic acid (BA) were linked neatly with the nucleoside drug zidovudine (AZT) through a molecular hybrid strategy to synthesize twenty of PTs-AZT conjugates for targeting HBV polymerase as well as sodium taurocholate cotransporting polypeptide (NTCP). The conjugates showed significant inhibitory effects on the secretion of HBsAg and HBeAg in HepG2.2.15 cells, and the activity on HBsAg were better. Moreover, HBV DNA replication was also notably suppressed after incubated with the conjugates. The IC₅₀ value of BA-AZT1 on HBsAg inhibition was 0.65 ± 0.07 μM, and it was 284.2 times and 442.2 times higher comparing to corresponding parent compound BA and AZT. Additionally, the therapeutic index (TI) was also improved by 87.8 times than AZT. And the IC₅₀ value of BA-AZT1 on inhibition of HBV DNA replication was 0.70 ± 0.02 μM, 10.4 times higher than that of AZT besides conspicuous TI. Molecular docking suggested that AZT skeleton of conjugate BA-AZT1 interacted with B region of HBV Polymerase reverse transcription region, and BA structure simultaneously targeted to C region of polymerase via hydrophobic chain, establishing strong binding interactions with the HBV Pol protein. In addition, docked with NTCP, BA-AZT1 with flat pentacyclic structure inserted into the interface and also formed hydrogen bonds, hydrophobic and van der Waals forces with the amino residue 157-165 of NTCP. Further SPR analysis demonstrated the binding affinity of BA-AZT1 to C region of polymerase was 19.55 μM, stronger than 53.21 μM of BA and 31.82 μM of AZT. BA-AZT1 selectively bound to the 157-165 epitopes of NTCP receptors in host cell but not PreS1 of virus. As a result, we deduced that the designed conjugates targeted NTCP and HBV polymerase, not only prevented HBV from entering host cells via selective binding NTCP, but also inhibited HBV DNA replication through obstructing the function of HBV polymerase, and it could potentially serve as a promising dual-functional and dual-target inhibitor with both replication and entry inhibition to exert anti-HBV activity.

News (Medical) associated with Zidovudine

15 Oct 2024

·www.prnewswire.com

WARBURG PINCUS STRENGTHENS ITS EUROPEAN BUSINESS AND GLOBAL HEALTHCARE GROUP WITH TWO NEW SENIOR ADVISERS

Seasoned industry experts will advise Warburg Pincus on new investments and drive value creation across its portfolio companies LONDON and BERLIN, Oct. 15, 2024 /PRNewswire/ -- Warburg Pincus, a leading global growth investor, today announced the appointment of Dr. Francesco Granata and Dr. Axel Herberg as Senior Advisers working with its European business and global healthcare group. Dr. Granata and Dr. Herberg will support Warburg Pincus in the identification and evaluation of new potential investment opportunities across Europe for its funds, and they bring deep expertise and connectivity within the pharmaceutical, life sciences, medical device and healthcare sectors. The senior adviser appointments follow the recent announcement of Enovo Life Sciences, a new life sciences platform institutionally capitalized by funds advised by Warburg Pincus and led by life sciences industry veterans, Mario Philips and Roel Gordijn. These announcements demonstrate the continued momentum in Warburg Pincus's European business. Jake Strauss, a Managing Director in the global healthcare group, was recently announced as head of the firm's European healthcare efforts and Tobias Weidner, recently joined the firm as a Managing Director leading industrials in Europe. Recent European investments include Aztec, Specialist Risk Group and Epassi. Dr. Herberg brings wide-ranging experience as an operator and investor. He is a member of various supervisory boards and is an active entrepreneur. He joined the Gerresheimer Group in 1992 and developed the company to a leading systems and solutions provider to the pharma and biotech industries and is currently Chairman of the Supervisory Board. Between 2010 and 2017, Dr. Herberg was a Partner at Blackstone, responsible for the private equity business in the German-speaking regions of Europe. Dr Herberg currently sits on the boards of Gerresheimer, Axplora, and Vetter Pharma. Dr. Granata has more than 40 years of experience in the pharmaceuticals and biotechnology industries. He was Executive Vice President and member of the Executive Committee at Biogen Idec; served as Group Vice President at Schering-Plough, and President of Schering-Plough Europe and Canada; and held various senior management positions at Pharmacia, Dompé Biotech, and Pfizer. He currently sits on the Boards of Italfarmaco and GreenBone Ortho. He is General Partner and co-founder of Venture Capital firm 3B Future. Jake Strauss, Managing Director at Warburg Pincus, said, "We are excited to be working with Francesco and Axel. They bring decades of invaluable experience and strong networks across Europe that will further enhance our ability to identify attractive investment opportunities for our funds where we can partner with management teams, entrepreneurs, and families to accelerate growth. Their experience will also be invaluable to our existing portfolio companies in allowing them to navigate the complex macroeconomic and technological drivers of change that are transforming their industries." Dr Axel Herberg said, "I am looking forward to working with the exceptional team at Warburg Pincus. The firm's strong reputation, deep sector expertise and recent growth in Europe, make this an exciting time to work with the European team." Dr Francesco Granata said, "Warburg Pincus has a long history of successfully partnering with founders and management teams and bringing deep expertise to help businesses build long-term sustainable growth. I look forward to working together to identify exciting new businesses and strong management teams driving innovation, technological change and improved patient outcomes across the healthcare sector." Funds advised by Warburg Pincus have been among the leading global growth investors in Europe and were one of the first to invest in Europe in 1983. In Europe, the Warburg Pincus funds have invested more than $14 billion in over 125 companies across more than 20 European countries. Warburg Pincus funds have invested over $18 billion in more than 189 innovative healthcare and life sciences companies around the world, including Bausch + Lomb, Ensemble Healthcare Partners, Global Healthcare Exchange, Modernizing Medicine, and Sotera Health. The firm has also notably been active in the European healthcare market including recent investments by the funds in Polyplus, Simtra BioPharma Solutions, Norstella and the START Center for Cancer Research. About Warburg Pincus Warburg Pincus LLC is a leading global growth investor. The firm has more than $83 billion in assets under management. The firm's active portfolio of more than 225 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Since its founding in 1966, Warburg Pincus has invested more than $117 billion in over 1,000 companies globally across its private equity, real estate, and capital solutions strategies. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information please visit . Follow us on LinkedIn. Media Contact Jenna Ward, Europe Communications Director M: +44 7570 844 338 E: [email protected] WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive Change

08 Aug 2024

·www.drugs.com

Abacavir Use Linked to Increased Incidence of MACE

THURSDAY, Aug. 8, 2024 -- For patients with HIV in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial, use of abacavir was associated with an increased incidence of major adverse cardiovascular events (MACE), according to a study presented at AIDS 2024, the 25th International AIDS Conference, held from July 22 to 26 in Munich. Carl J. Fichtenbaum, M.D., from the University of Cincinnati, and colleagues examined the role of prior and current use of antiretroviral agents (ART) on the development of MACE in a trial involving 7,769 participants aged 40 to 75 years on ART for at least 180 days. The median duration of ART use was 9.5 years, with variation by country. The researchers found that 22, 86, 49, and 47 percent of participants reported prior exposure to abacavir, tenofovir (TDF), thymidine analogs (AZT/d4T), and protease inhibitors (PIs), respectively. At study entry, 13, 61, 10, and 26 percent were using abacavir, TDF, AZT/d4T, and PIs, respectively. Entry regimens included two nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-NRTI, integrase strand transfer inhibitor, or PI (47, 25, and 19 percent, respectively). Both former and current use of abacavir was associated with a higher incidence of MACE in adjusted analyses including the baseline regimen. No association was seen for former or current use of other ART agents with MACE. "Former and current use of abacavir was associated with a higher incidence of subsequent major adverse cardiovascular events in the REPRIEVE trial," the authors write. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultAHAClinical Study

23 Jul 2024

·www.drugs.com

Exploratory Analysis Associates HIV Drug Abacavir with Elevated Cardiovascular Disease Risk in Large Global Trial

July 23, 2024 -- Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, according to an exploratory analysis from a large international clinical trial primarily funded by the National Institutes of Health (NIH). There was no elevated MACE risk for the other antiretroviral drugs included in the analysis. The findings will be presented at the 2024 International AIDS Conference (AIDS 2024) in Munich, Germany. The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled 7,769 study participants with HIV from 12 countries that found daily use of a cholesterol-fighting statin drug reduced the risk of major adverse cardiovascular events, such as heart attacks and strokes by more than one third. The REPRIEVE study team also performed statistical analyses to assess whether select ARVs were associated with MACE risk among study participants, all of whom had low-to-moderate cardiovascular disease risk. The ARVs selected for analysis had previously been linked to cardiovascular risk and included abacavir, tenofovir, zidovudine, stavudine, and drugs from a class called protease inhibitors (PIs). All were taken as part of multi-drug ART regimens. Overall, 22% of study participants reported prior exposure to abacavir, 86% to tenofovir, 49% to zidovudine or stavudine, and 47% to PIs. At study entry, 13% of participants were taking abacavir, 61% were taking tenofovir, 10% were taking zidovudine or stavudine, and 26% were taking PIs. In the investigators’ analyses, participants with prior and current use of abacavir had a 50% and 42% elevated risk of MACE, respectively, compared to participants with no abacavir exposure. Former or current use of other ARVs was not associated with any change in MACE risk, and the co-administration of common ARV drug classes as part of an ART regimen did not impact the elevated MACE risk among participants with current or prior abacavir exposure. According to the authors, these findings align with previous studies that also identified an elevated cardiovascular disease risk associated with abacavir. They suggest that more research is needed to better understand the increased risk observed in this analysis, including how these findings should be considered in the context of known cardiovascular disease risk factors, such as dyslipidemia, diabetes and hypertension, for people with HIV. More information about the REPRIEVE trial is available at ClinicalTrials.gov under identifier NCT02344290. CJ Fichtenbaum et al. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. International AIDS Conference. Friday, July 26, 2024. Sarah Read, M.D., deputy director, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH is available to discuss this research. NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical StudyClinical ResultAHA

100 Deals associated with Zidovudine

External Link

KEGG	Wiki	ATC	Drug Bank
D00413	Zidovudine	J05AF01	DB00495

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	US	ViiV Healthcare Co.	19 Mar 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	US	Glaxo Wellcome SA	31 Aug 2001
Pregnancy	Phase 3	PR	Glaxo Wellcome SA	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Not Applicable	Lymphoproliferative Disorders	24	GARD regimen	ngmnecqmki(bfpdsorhgp) = ewpxrqzynk dsgfxgkrpv (eohegvbdgj, 45.8 - 85.2) View more	-	11 Dec 2023
NCT03988452 (NADIA, Pubmed \| Lancet HIV)	Phase 3	HIV Infections Second line	465	Dolutegravir	oszxgwqhga(lykcwmnmnk) = eiqrlcwasy xpghvebgpw (enzxcdchrb )	Positive	20 Apr 2022
				Ritonavir-boosted darunavir	oszxgwqhga(lykcwmnmnk) = tficlwcgep xpghvebgpw (enzxcdchrb )
NCT01818258 (IMPAACT P1092, CTgov)	Phase 4	Malnutrition \| HIV Seropositivity	52	Zidovudine+Lamivudine+Lopinavir/Ritonavir (Severe Malnutrition)	hajzxzjgmd(aehbipksfa) = ugqcfevttd evwiredjzs (cpmzgrujys, hwfyczqhhp - pdvblnjezq) View more	-	12 Aug 2021
				Zidovudine+Lamivudine+Lopinavir/Ritonavir (Normal Nutrition/Mild Malnutrition)	hajzxzjgmd(aehbipksfa) = fjaptzkwrs evwiredjzs (cpmzgrujys, iwrflydivk - wsmakwrfre) View more
NCT01386970 (CTgov)	Phase 4	HIV Infections	43	zidovudine 300mg+lamivudine 150mg as Combivir (HIV-negative)	mcuoefslyn(ujhfqzemqk) = xhvreqbrxs chittfmlml (szcobhyokv, kvalwvqdvb - madmnzyrfi) View more	-	16 Mar 2020
				zidovudine 300mg+lamivudine 150mg as Combivir (HIV-infected)	mcuoefslyn(ujhfqzemqk) = qlzjnmleyw chittfmlml (szcobhyokv, ivshydbqqu - wposvcvpia) View more
IAS2020	Not Applicable	Second line	1,017	Tenofovir/3TC	slgxxpniki(npyeootcft) = rxzcimkowk kiadrtowol (yjcoxvvxfo ) View more	-	01 Jan 2020
				Zidovudine/3TC	slgxxpniki(npyeootcft) = ultewwosll kiadrtowol (yjcoxvvxfo ) View more
NCT01964755 (CTgov)	Phase 2	Post-transplant lymphoproliferative disorder \| Acquired Immunodeficiency Syndrome \| Epstein-Barr virus associated Hodgkin's Lymphoma ... View more	6	Zidovudine+leucovorin+Doxorubicin+Hydroxyurea+Rituximab+Methotrexate	ankovekxwn(nksqopbxod) = nfevchyozq tdbtadxlvd (jtozeisclu, rsryidtpds - uhjuinyiwa) View more	-	23 Sep 2019
NCT00102960 (CHER, CTgov)	Phase 3	HIV Infections	377	Zidovudine+Abacavir sulfate+Didanosine+efavirenz+Lamivudine+Nevirapine+Lopinavir/ritonavir	dvejpjdvhu(hoghjlzfjf) = ekyzfzesau ebuvpbbywx (fbyllwuvvf, cuwsmatwdb - zpcbhbmyht)	-	30 Nov 2018
NCT00084149 (CTgov)	Phase 2	HIV Infections	54	Cyclosporine (Cyclosporine)	yomzsahkgm(qqhqxeagab) = ebaqiwpkxr ywcoielltv (jtrvwqtutn, wugykryqql - byjdfgxdkf) View more	-	13 Sep 2018
				Cyclosporine (No Cyclosporine)	yomzsahkgm(qqhqxeagab) = kmhxjontgc ywcoielltv (jtrvwqtutn, anepkejkyy - ssrarnjhoi) View more
NCT00993031 (PROMOTE-PIs \| PROMOTE, CTgov)	Phase 3	HIV Infections \| Malaria	389	Zidovudine+Lamivudine+Lopinavir/ritonavir (Group A)	opidnyfxfs(nqaoyathlk) = bdublbubxc wrjeshdnaz (iqhdbpxvcc, ogfawhpuez - fgvunymdnq) View more	-	02 Dec 2017
				Zidovudine+Efavirenz+Lamivudine (Group B)	opidnyfxfs(nqaoyathlk) = iqenoaidoi wrjeshdnaz (iqhdbpxvcc, yzrwberwlh - bkcbhvpsci) View more
Pubmed \| Trop Med Int Health	Not Applicable	Metabolic Syndrome First line	1,166	ART containing zidovudine	fdefcngwpg(lzseeuoybz) = tlazeyrsms pdwnawvcho (bbhzkafadv )	-	01 Jun 2017
				ART containing tenofovir disoproxil	fdefcngwpg(lzseeuoybz) = ppnqotgbef pdwnawvcho (bbhzkafadv )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis